Drugs / SB719125
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00058526 | Mar 2003 → Sep 2006 | breast neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB719125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00058526 ↗ |
| Modality | Protein / enzyme biologic | “a protein-based immunotherapeutic” PMID 26993131 ↗ Mar 2016 |
| Route | Intramuscular | “Intramuscular injection” NCT00058526 ↗ |